On Tuesday, Calumet received an upgrade to its Relative Strength (RS) Rating, from 67 to 77.
How To Invest In Stocks In Both Bull And Bear Markets
IBD's proprietary RS Rating tracks market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the trailing 52 weeks compares to other publicly traded companies.
Over 100 years of market history reveals that the best-performing stocks typically have an 80 or better RS Rating as they begin their biggest runs. See if Calumet can continue to rebound and hit that benchmark.
Calumet is not currently offering a proper buying opportunity. See if the stock goes on to build a base that could kick off a new climb.
Calumet posted 0% EPS growth last quarter, while sales growth came in at -1%.
The company earns the No. 18 rank among its peers in the Oil & Gas-Refining/Marketing industry group. UGI, Targa Resources and Global Partners are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
